Literature DB >> 24503688

Direct decompressive surgery followed by radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression: a meta-analysis.

Chang-Hyun Lee1, Ji-Woong Kwon, Jaebong Lee, Seung-Jae Hyun, Ki-Jeong Kim, Tae-Ahn Jahng, Hyun-Jib Kim.   

Abstract

STUDY
DESIGN: A systemic review and meta-analysis.
OBJECTIVE: To compare the ambulatory status and survival for metastatic epidural spinal cord compression (MESCC) in patients treated with direct decompressive surgical resection (DDSR) followed by radiotherapy (RTx) with those in patients treated with RTx alone. SUMMARY OF BACKGROUND DATA: Surgical techniques have remarkably evolved from decompressive laminectomy without ventral tumor excision to DDSR, which has displayed favorable outcomes since the 2000s. RTx alone has also evolved and is regarded to have accomplished outcome comparable with that of the surgery. The optimal treatment of MESCC has not been clearly defined yet.
METHODS: We searched MEDLINE, EMBASE, and the Cochrane library in July 2013. Comparative studies enrolled patients with similar performance, primary cancer, age, and sex at the baseline state were included. Outcome measures included ambulatory status and overall survival rate. We did a fixed-effects meta-analysis of the ambulatory status and survival in patients with MESCC compared with DDSR+RTx and RTx alone.
RESULTS: Five studies were used to obtain data from 238 and 1137 patients treated with DDSR+RTx and RTx alone, respectively. The DDSR+RTx group displayed substantial improvement in ambulatory status after the treatment that was superior to the improvement in the RTx-alone group (relative risk [RR], 1.43; 95% confidence interval [CI], 1.14-1.78) in a fixed-effects model and significantly lower deterioration after treatment than the RTx group (RR, 0.35; 95% CI, 0.19-0.63). The DDSR+RTx group showed significant improvement in the survival rate at 6 months post-treatment (RR, 1.21; 95% CI, 1.09-1.33). Similar findings were observed at 12 months post-treatment (RR, 1.32; 95% CI, 1.12-1.56).
CONCLUSION: The meta-analysis indicates that DDSR+RTx may produce better clinical improvement of ambulation status and survival than RTx alone in the treatment of MESCC. Additional prospective studies are warranted to better address this question. LEVEL OF EVIDENCE: 1.

Entities:  

Mesh:

Year:  2014        PMID: 24503688     DOI: 10.1097/BRS.0000000000000258

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  19 in total

1.  Patient-reported outcomes after surgical stabilization of spinal tumors: symptom-based validation of the Spinal Instability Neoplastic Score (SINS) and surgery.

Authors:  Ibrahim Hussain; Ori Barzilai; Anne S Reiner; Natalie DiStefano; Lily McLaughlin; Shahiba Ogilvie; Mark Bilsky; Ilya Laufer
Journal:  Spine J       Date:  2017-07-13       Impact factor: 4.166

2.  Reducing kyphotic deformity by posterior vertebral column resection with 360° osteosynthesis in metastatic epidural spinal cord compression (MESCC).

Authors:  Marc Dreimann; Michael Hoffmann; Lennart Viezens; Lukas Weiser; Patrick Czorlich; Sven Oliver Eicker
Journal:  Eur Spine J       Date:  2016-10-11       Impact factor: 3.134

3.  The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases.

Authors:  Rachit Kumar; Anick Nater; Ahmed Hashmi; Sten Myrehaug; Young Lee; Lijun Ma; Kristin Redmond; Simon S Lo; Eric L Chang; Albert Yee; Charles G Fisher; Michael G Fehlings; Arjun Sahgal
Journal:  Neurooncol Pract       Date:  2015-07-27

4.  Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis.

Authors:  Chang-Hyun Lee; Chun Kee Chung; Tae-Ahn Jahng; Ki-jeong Kim; Chi Heon Kim; Seung-Jae Hyun; Hyun-Jib Kim; Sang Ryong Jeon; Ung-Kyu Chang; Sun-Ho Lee; Seong-Hwan Moon; Haroon Majeed; Dan Zhang; Gwenaelle Gravis; Christine Wibmer; Naresh Kumar; Kyung Yun Moon; Jin Hoon Park; Emeline Tabouret; Stephane Fuentes
Journal:  J Neurooncol       Date:  2015-05-07       Impact factor: 4.130

Review 5.  The current status and future of radiotherapy for spinal bone metastases.

Authors:  Yasuo Ejima; Yoshiro Matsuo; Ryohei Sasaki
Journal:  J Orthop Sci       Date:  2015-04-11       Impact factor: 1.601

6.  Ultra Long Construct Minimally Invasive Spinal Stabilization Using Percutaneous Pedicle Screws in the Treatment of Symptomatic Multicentric Spinal Metastasis.

Authors:  Chee Kean Lee; Chris Yin Wei Chan; Mun Keong Kwan
Journal:  Asian Spine J       Date:  2015-12-08

7.  The neurological outcome of radiotherapy versus surgery in patients with metastatic spinal cord compression presenting with myelopathy.

Authors:  Keiichiro Iida; Yoshihiro Matsumoto; Nokitaka Setsu; Katsumi Harimaya; Kenichi Kawaguchi; Mitsumasa Hayashida; Seiji Okada; Yasuharu Nakashima
Journal:  Arch Orthop Trauma Surg       Date:  2017-10-14       Impact factor: 3.067

8.  Minimally Invasive Spinal Stabilization Using Fluoroscopic-Guided Percutaneous Screws as a Form of Palliative Surgery in Patients with Spinal Metastasis.

Authors:  Mun Keong Kwan; Chee Kean Lee; Chris Yin Wei Chan
Journal:  Asian Spine J       Date:  2016-02-16

Review 9.  Spine radiosurgery for the local treatment of spine metastases: Intensity-modulated radiotherapy, image guidance, clinical aspects and future directions.

Authors:  Fabio Ynoe de Moraes; Neil Kanth Taunk; Ilya Laufer; Wellington Furtado Pimenta Neves-Junior; Samir Abdallah Hanna; Heloisa de Andrade Carvalho; Yoshiya Yamada
Journal:  Clinics (Sao Paulo)       Date:  2016-02       Impact factor: 2.365

10.  Who are the Best Candidates for Decompressive Surgery and Spine Stabilization in Patients With Metastatic Spinal Cord Compression?: A New Scoring System.

Authors:  Mingxing Lei; Jianjie Li; Yaosheng Liu; Weigang Jiang; Shubin Liu; Shiguo Zhou
Journal:  Spine (Phila Pa 1976)       Date:  2016-09-15       Impact factor: 3.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.